U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07216079) titled 'Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan' on Oct. 09.
Brief Summary: This is an open-label, multi-center, single group, Phase 3 study for treatment with rilzabrutinib.
The purpose of this study is to provide continuation of rilzabrutinib treatment to adult participants with ITP who have completed the LTE of the LUNA 3 study in Japan, demonstrating clinically meaningful benefit as judged by the Investigator.
Study Start Date: Oct. 15
Study Type: INTERVENTIONAL
Condition:
Immune Thrombocytopenia
Intervention:
DRUG: rilzabrutinib
Pharmaceutical form:Tablet-Route of admi...